| Drug Name |
Sufentanil |
| Drug ID |
BADD_D02082 |
| Description |
Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes.
Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments [L4717]. Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately [L4718].
The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 [L4717].
This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural administration [L4717], [A39633]. |
| Indications and Usage |
The indications for this drug are as follows:
1. As an analgesic adjunct in the maintenance of balanced general anesthesia in patients who are intubated and ventilated.
2. As a primary anesthetic agent for the induction and maintenance of anesthesia with 100% oxygen in patients undergoing major surgical procedures, in patients who are intubated and ventilated, such as cardiovascular surgery or neurosurgical procedures in the sitting position, to provide favorable myocardial and cerebral oxygen balance or when extended postoperative ventilation is anticipated.
3. For epidural administration as an analgesic combined with low dose (usually 12.5 mg per administration) bupivacaine usually during labor and vaginal delivery
4. The sublingual form is indicated for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments.
[FDA label] |
| Marketing Status |
approved; investigational |
| ATC Code |
N01AH03 |
| DrugBank ID |
DB00708
|
| KEGG ID |
D05938
|
| MeSH ID |
D017409
|
| PubChem ID |
41693
|
| TTD Drug ID |
D0D8DD
|
| NDC Product Code |
0406-0310; 67651-0327; 0406-0330; 61621-430 |
| UNII |
AFE2YW0IIZ
|
| Synonyms |
Sufentanil | Sulfentanyl | Sulfentanil | Sufenta | Sufentanil-Ratiopharm | Sufentanil Ratiopharm | SufentanilRatiopharm | Sufentanil Curasan | Curasan, Sufentanil | Sufentanil-Hameln | Sufentanil Hameln | SufentanilHameln | R-30730 | R 30730 | R30730 | Sufentanil Citrate | Citrate, Sufentanil |
